Markets:

Overview

News

Currencies

International

Treasuries

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

72.89 -0.56 (-0.76%)

Streaming Delayed Price Updated: 11:34 AM EDT, Aug 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical ↗

August 31, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)...

Via Benzinga

Cytokinetics, Incorporated (CYTK) Q2 2021 Earnings Call Transcript ↗

August 06, 2021

CYTK earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Cytokinetics: Q2 Earnings Insights ↗

August 05, 2021

Shares of Cytokinetics (NASDAQ:CYTK) moved lower in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 26.47% over the past...

Via Benzinga

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗

May 01, 2021

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...

Via Benzinga

The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts ↗

August 10, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (...

Via Benzinga

Cell Analysis Instruments Provider Cytek Biosciences Kick Starts Trading After Pricing IPO At $17 ↗

July 23, 2021

Cytek Biosciences Inc (NASDAQ: CTKB) shares started trading today after its initial public offering was priced to raise about $200 million for the cell-analysis Company....

Via Benzinga

Topics Initial Public Offering

Why Cytokinetics (CYTK) Shares Are Trading Higher Today? ↗

July 20, 2021

Cytokinetics Incorporated (NASDAQ: CYTK) shares continue to move forward after it announced positive REDWOOD-HCM Phase 2 data for CK-274 and garnered favorable comments...

Via Benzinga

10 Biggest Price Target Changes For Tuesday ↗

July 20, 2021

Citigroup boosted International Business Machines Corporation (NYSE:

Via Benzinga

Why Is Cytokinetics Inc. (NASDAQ: CYTK) The Best Stock of the Day? ↗

July 19, 2021

Founded in 1997, Cytokinetics Inc. focuses on muscle biology, developing muscle activators and inhibitors that improve overall function. These medications most often serve...

Via Benzinga

Dow on Pace for Worst Day of 2021 as Covid-19 Fears Weigh ↗

July 19, 2021

The Dow Jones Industrial Average is down more than 760 points at midday and is eyeing its worst daily drop for 2021.

Via Talk Markets

Topics Stocks

The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street ↗

July 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated...

Via Benzinga

54 Biggest Movers From Yesterday ↗

July 20, 2021

Gainers Aehr Test Systems (NASDAQ: AEHR) shares climbed 87.9% to close at $6.39 on Monday after the company won a $10.8 million single purchase order from its lead silicon...

Via Benzinga

Here's Why Cytokinetics Is Rocketing Higher Today ↗

July 19, 2021

The company's new heart drug candidate produced encouraging clinical trial results.

Via The Motley Fool

Mid-Day Market Update: Crude Oil Dips 6%; Cytokinetics Shares Spike Higher ↗

July 19, 2021

Midway through trading Monday, the Dow traded down 2.28% to 33,896.40 while the NASDAQ fell 1.31% to 14,238.93. The S&P also fell, dropping 1.74% to 4,251.79. The U.S. has the...

Via Benzinga

Topics Stocks

30 Stocks Moving In Monday's Mid-Day Session ↗

July 19, 2021

Gainers Cytokinetics, Incorporated (NASDAQ: CYTK) jumped 56.4% to $30.07 after the company disclosed topline results from Cohorts 1 and 2 of REDWOOD-HCM. Aehr Test Systems (...

Via Benzinga

CYTK Stock Flies High on Exciting Drug Trial Results ↗

July 19, 2021

CYTK stock is being boosted by bullish biopharma buyers today. The company is reporting with optimism regarding its newest HCM treatment.

Via InvestorPlace

How Strong Cytokinetics Test Results Could Undermine Bristol Myers' $13.1 Billion Buyout ↗

July 19, 2021

Cytokinetics said Monday its treatment improved blood flow for patients with a genetic heart disease, and the biotech stock sprinted.

Via Investor's Business Daily

Mid-Morning Market Update: Markets Open Lower; AutoNation Profit Beats Estimates ↗

July 19, 2021

Following the market opening Monday, the Dow traded down 2.31% to 33,885.81 while the NASDAQ fell 1.67% to 14,186.04. The S&P also fell, dropping 1.94% to 4,243.38. The U.S....

Via Benzinga

Topics Stocks

Stocks That Hit 52-Week Highs On Monday ↗

July 19, 2021

On Monday morning, 20 companies achieved new highs for the year. Areas of Significance: The largest company by market cap to break to a new 52-week high was PepsiCo...

Via Benzinga

Cytokinetics Shares Gain On Positive Data From Heart Disease Candidate ↗

July 19, 2021

Cytokinetics Incorporated (NASDAQ: CYTK) has announced positive topline results from Cohorts 1 and 2 of REDWOOD-HCM Phase 2 trial of CK-3773274 (CK-274) in...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

July 19, 2021

Gainers NRX Pharmaceuticals (NASDAQ:NRXP) stock moved upwards by 67.6% to $14.28 during Monday's pre-market session. The company's market cap stands at $684.2...

Via Benzinga

Cytokinetics Post-Hoc Data Suggests Omecamtiv Mecarbil Works Better In High-Risk Patients For Heart Failure ↗

May 17, 2021

Cytokinetics Incorporated (NASDAQ: CYTK) announced secondary data analysis from the GALACTIC-HF trial evaluating omecamtiv mecarbil in patients with heart...

Via Benzinga

Cytokinetics Inc (CYTK) Q1 2021 Earnings Call Transcript ↗

May 07, 2021

CYTK earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics ↗

May 03, 2021

Cytokinetics Inc (NASDAQ: CYTK) revealed in an SEC filing that Astellas Pharma Inc (OTCMKTS: ALPMY) is walking away from a pact to research and...

Via Benzinga

Topics Regulatory Compliance

The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom ↗

May 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.